TrialLancet (London, England)2017

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

Arjun V Balar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.